Zura Bio (ZURA) AI Stock Analysis

• Market Cap: $81.02M
• Dividend Yield: N/A
• Average Volume (3M): 286.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: N/A
• EPS Growth: 86.65%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.58
• Shares Outstanding: 68,375,000
• 10 Day Avg. Volume: 363,150
• 30 Day Avg. Volume: 286,204
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.80
• Price Target Upside: 908.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Zura Bio's financial challenges significantly impact its stock score, with no revenue and increasing losses offset by a strong cash position. Technical indicators suggest bearish momentum, while valuation remains weak due to lack of earnings. Recent corporate events highlight strategic progress that could drive future growth, but current financial and operational issues weigh heavily on the score.

Positive Factors

Clinical Progress

ZURA plans to initiate a Phase 2 trial of lead asset tibulizumab in hidradenitis suppurativa (HS), and they now have an active IND for this indication.

Financial Stability

Zura ended 2024 with roughly $176.5M in cash and cash equivalents, which management expects to provide an operational runway through 2027.

Regulatory Interactions

The timely launch of the Phase 2 TibuSURE trial in systemic sclerosis aligns with ZURA's stated timeline, indicating positive interactions with the FDA.

Negative Factors

Clinical Data Concerns

There is a lackluster clinical data to date, with no clear dose-dependent response in B cell count reductions and an increase in IL-17A target engagement observed at the highest dose in the post-dosing follow-up period.

Market Perception

ZURA has fallen out of investor attention (-50% YTD vs. XBI -6.5%) in a dislocation largely driven by a perceived catalyst vacuum rather than any fundamental change to the story.

Regulatory Risks

The broader development-stage biotech landscape has seen heightened regulatory risks stemming from the recent FDA shakeup.

Zura Bio Business Overview & Revenue Model

Company Description

Zura Bio (ZURA) is a biotechnology company focused on the development and commercialization of innovative therapies for immune-mediated and fibrotic diseases. The company operates within the healthcare sector, specifically targeting the biopharmaceutical industry. Zura Bio's core products are centered around its proprietary drug candidates that aim to address unmet medical needs by modulating complex biological pathways involved in immune system regulation and tissue fibrosis.

How the Company Makes Money

Zura Bio generates revenue through the development and commercialization of its proprietary drug candidates. The company's primary revenue streams include licensing agreements, partnerships with other pharmaceutical companies, and potential sales of successfully developed therapies. Zura Bio collaborates with strategic partners for clinical development, regulatory approval, and distribution of its products, which can result in milestone payments and royalties. Additionally, the company may engage in research and development collaborations that provide funding and resource sharing to advance its product pipeline.

Zura Bio Financial Statement Overview

Summary

Zura Bio faces financial challenges with no revenue generation and increasing losses. However, its strong cash position and absence of debt offer short-term stability. The company must improve operational efficiencies and explore revenue-generating strategies to ensure long-term viability.

Income Statement

Zura Bio has consistently reported zero revenue over the past three years, with increasing net losses. This reflects a challenging financial position in terms of generating income. The negative EBIT and EBITDA margins further highlight inefficiencies in cost management or lack of operational revenues.

Balance Sheet

The balance sheet shows a strong cash position with no debt, which provides a buffer against operational losses. The company's equity has significantly improved over the years, moving from negative to positive, indicating some financial recovery. However, the lack of revenue generation is a concern despite the strong cash reserves.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. While financing cash flow is positive, suggesting successful fundraising efforts, reliance on external financing could be risky without revenue improvement.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00
	EBIT
-55.19M	-62.64M	-2.68M	-1.09M
	EBITDA
-55.19M	-60.56M	-27.33M	8.42M
	Net Income Common Stockholders
-45.39M	-60.36M	3.55M	8.42M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
176.50M	99.81M	13.79K	4.72M
	Total Assets
179.53M	100.84M	141.51M	4.72M
	Total Debt
0.00	0.00	355.60K	0.00
	Net Debt
-176.50M	-99.81M	341.81K	-4.72M
	Total Liabilities
19.51M	21.29M	14.82M	39.00K
	Stockholders Equity
146.81M	59.33M	-32.06M	4.68M
Cash Flow		Free Cash Flow
-28.15M	-23.05M	-13.07M	-1.10M
	Operating Cash Flow
-28.08M	-15.05M	-1.07M	-1.10M
	Investing Cash Flow
-5.08M	-8.00M	-12.00M	-139.38M
	Financing Cash Flow
109.84M	121.29M	355.60K	141.21M

Zura Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Negative. The current price of 1.17 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.42, and below the 200-day MA of 2.98, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.82 is Neutral, neither overbought nor oversold. The STOCH value of 19.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZURA.

Zura Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	66 Neutral	$1.58B	―	-9.85%	―	56.60%	-403.56%
ZLAB	59 Neutral	$4.17B	―	-31.41%	―	49.59%	24.92%
ANAB	57 Neutral	$564.27M	―	-182.71%	―	432.03%	14.41%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
ZURA	43 Neutral	$81.02M	―	-44.03%	―	―	86.65%
IMVT	43 Neutral	$2.58B	―	-74.17%	―	―	-43.10%
IBRX	41 Neutral	$2.53B	―	78.99%	―	2270.58%	46.82%

Zura Bio Corporate Events

Zura Bio to Participate in Global Healthcare Conference

On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.

Zura Bio Highlights Strategic Goals and Clinical Advances

Zura Bio Limited has updated its corporate presentation to highlight significant developments in its operations and strategic goals. The company is advancing clinical trials for its high-potential biologics targeting multi-billion-dollar markets, with the tibulizumab Phase 2 study for systemic sclerosis ongoing. With an experienced leadership team, Zura Bio aims to leverage strategic milestones and financial strength to support operations through 2027, potentially driving significant value creation and industry positioning.